All In Biotech

Drug Trial Radar · NCT00700310

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Last checked: Nov 19, 2026Latest source record: Jan 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 712 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

712

Actual

Start

Aug 2008

Primary completion

Aug 2009

Study completion Jan 2010

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jun 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.

Conditions

  • Refractory Partial Seizures

Interventions

  • perampanelDrug

    2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.

  • perampanelDrug

    4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.

  • perampanelDrug

    8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.

  • PlaceboDrug

    Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)Time frame: Baseline (Pre-randomization) through Week 19

Locations

137 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    Clayton, Australia

  • Site not named

    Fitzroy, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    West Heidelberg, Australia

  • Site not named

    Woodville, Australia

  • The Queen Elizabeth Hospital

    Woodville, South Australia, Australia

  • Site not named

    Woodville South, South Australia, Australia

  • Site not named

    Clayton, Victoria, Australia

  • Site not named

    Fitzroy, Victoria, Australia

  • Site not named

    Heidelberg, Victoria, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Brno, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Kehl-Kork, Germany

  • Site not named

    Konigstein-Falkenstein, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Marburg, Germany

  • Site not named

    München, Germany

  • Site not named

    München, Germany

  • Site not named

    Ulm, Germany

  • Site not named

    Westerstede, Germany

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Site not named

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital

    Kowloon, Hong Kong

  • United Christian Hospital

    Kowloon, Hong Kong

  • Site not named

    Kowloon, Hong Kong

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.